Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF)-Trial Running title: Goette et al.; The ANTIPAF Trial
نویسندگان
چکیده
University Hospital Magdeburg, Magdeburg; Dept of Cardiology & Intensive Care Med, St. Vincenz-Hospital Paderborn, Paderborn; Mühldorf, Germany; Dept of Cardiology & Angiology, University Hospital Münster, Münster, Germany; University of Birmingham Centre for Cardiovascular Sciences, Birmingham, United Kingdom; Institut für klinischkardiovaskuläre Forschung (IKKF), Munich; Klinik und Poliklinik für Neurologie, CharitéUniversitätsmedizin Berlin, Berlin, Germany; University of Rochester Medical Center, Heart Research Follow-up Program, Rochester, NY; Dept of Internal Med I, University Hospital Munich (LMU), Munich; Dept of Medical Biometry & Epidemiology, University Medical Ctr Hamburg-Eppendorf, Hamburg; University Heart Center Hamburg, Hamburg, Germany
منابع مشابه
Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial.
BACKGROUND Unlike antiarrhythmic drugs, the safety and beneficial effects of angiotensin II receptor blockade (ARB) in patients with structural heart disease is well established. The clinical efficacy of ARBs to prevent atrial fibrillation (AF) so far only has been shown in patients with structural heart disease. Here, we report the primary outcome of the Angiotensin II-Antagonist in Paroxysmal...
متن کاملData mining experiments on the Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF-AFNET 2) trial: 'exposing the invisible'.
Aims The aims of this study include (i) pursuing data-mining experiments on the Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF-AFNET 2) trial dataset containing atrial fibrillation (AF) burden scores of patients with many clinical parameters and (ii) revealing possible correlations between the estimated risk factors of AF and other clinical findings or measurements provide...
متن کاملRegulation of angiotensin II receptor subtypes during atrial fibrillation in humans.
BACKGROUND Previous studies have suggested that atrial fibrillation (AF) is associated with the activation of the atrial angiotensin system. However, it is not known whether the expression of angiotensin II receptors changes during AF. The purpose of this study was to determine the atrial expression of angiotensin II type 1 and type 2 receptors (AT(1)-R and AT(2)-R) in patients with AF. METHO...
متن کاملAngiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression.
BACKGROUND Increased levels of inflammatory markers are predictors of thromboembolic events during atrial fibrillation (AF). Increased endocardial expression of adhesion molecules (ie, vascular cell adhesion molecule [VCAM] and intercellular adhesion molecule [ICAM]) could be an important link between initiation of inflammatory and prothrombogenic mechanisms responsible for thrombus development...
متن کاملNew Insights On Ablation Of Persistent Atrial Fibrillation: Evidence From The SARA Trial.
Since Haissaguerre et al first described the pathogenic role of pulmonary vein firing as a crucial mechanism triggering atrial fibrillation, catheter ablation has been recommended as a curative treatment. Several trials have demonstrated that ablation is an effective treatment in most patients with paroxysmal atrial fibrillation and low-grade remodelled atria. In patients with persistent AF, th...
متن کامل